ArticleMediators of inflammation2023
Analysis of the Influencing Factors of Tumor Volume, Body Immunity, and Poor Prognosis after
Article in Mediators of inflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.
- Neutrophil-To-Lymphocyte Ratio as a Prognostic Indicator in Thyroid Cancer.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Efficacy and safety of 125I seed implantation combined with thyroid-stimulating hormone suppression therapy in cervical lymph node metastases of differentiated thyroid carcinoma.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the influencing factors of tumor volume, body immunity, and poor prognosis after Methods: A total of 104 patients with differentiated TC who were treated with Results: The total effective rate of patients in the low- and high-dose groups was 78.85% and 82.69%, respectively ( Conclusion: The efficacy of low-dose and high-dose
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.